Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Alembic Limited is an India-based pharmaceutical company operating across generic formulations, active pharmaceutical ingredients (APIs), and R&D services. The company has significant exposure to the US generics market through its USFDA-approved manufacturing facilities in Gujarat, alongside a domestic branded formulations business serving Indian hospitals and retail pharmacies. The stock trades on regulatory approval cycles for complex generics, US market pricing dynamics, and domestic prescription volume growth.
Alembic generates revenue through a vertically integrated model: manufacturing APIs in-house reduces COGS for formulations, creating 68.8% gross margins. The US business monetizes first-to-file and limited-competition generics with 6-18 month exclusivity windows before commoditization. India operations leverage a 1,500+ person sales force for branded generics with 15-25% price premiums over unbranded equivalents. The 140% net margin (likely inflated by one-time gains or asset sales) is abnormal; normalized margins likely run 12-18%. Pricing power exists in niche US generics and branded India portfolio, but erodes rapidly in competitive segments.
USFDA approval announcements for complex generics (injectables, controlled substances) - each approval can add $10-50M annual revenue potential
US generic pricing trends - industry-wide erosion of 10-20% annually compresses margins despite volume growth
USFDA inspection outcomes for Gujarat facilities - warning letters trigger 20-30% stock declines; clearances drive 10-15% rallies
India prescription growth rates - 8-12% volume growth in chronic segments (diabetes, hypertension) drives domestic revenue
Rupee/USD exchange rate - 70% of costs in INR, 40-45% of revenue in USD creates natural hedge but volatility impacts reported earnings
US generic pricing deflation - industry consolidation among buyers (CVS/Aetna, Cigna/Express Scripts) increases purchasing power, driving 10-20% annual price erosion in competitive molecules. Limited-competition products face biosimilar and authorized generic threats.
Regulatory compliance burden - USFDA inspections occur every 18-24 months; Form 483 observations or warning letters halt new approvals and can trigger product recalls. Remediation costs $5-15M per facility and delays revenue 6-18 months.
India price control expansion - National Pharmaceutical Pricing Authority (NPPA) caps prices on essential medicines list, covering 20-25% of Alembic's domestic portfolio. Further expansion to 30-35% of molecules would compress India margins by 200-300bps.
Intensifying US generic competition - 8-12 ANDA approvals per molecule in oral solids creates commoditization within 12 months. Indian competitors (Sun Pharma, Dr. Reddy's, Cipla) have larger US sales forces and broader portfolios, winning formulary access.
Limited differentiation in India branded generics - 15,000+ pharma companies compete in fragmented market. Alembic lacks blockbuster brands or therapy leadership; relies on sales force productivity (₹8-12 lakh per rep annually) rather than product superiority.
Elevated capex intensity - $0.5B annual capex (23% of revenue) for facility upgrades, capacity expansion, and compliance retrofits strains free cash flow. $0.4B FCF provides 1.4% yield, limiting buyback/dividend capacity.
Working capital volatility - 1.87x current ratio adequate but inventory builds (3-6 months for API/formulation production cycles) and receivables stretching (US wholesalers extending terms to 75-90 days) can absorb $100-200M cash in growth quarters.
low - Pharmaceutical demand is non-discretionary with 85-90% of volume driven by chronic disease management (diabetes, cardiovascular, CNS disorders). US generic prescriptions grow 2-4% annually regardless of GDP. India volumes correlate loosely with middle-class expansion and insurance penetration, not quarterly GDP fluctuations. However, hospital capex (affecting institutional sales) and elective procedure volumes show mild cyclicality.
Minimal direct impact given zero debt (0.00 D/E ratio). Rising US rates strengthen USD vs INR, benefiting dollar-denominated revenue translation by 2-3% per 5% currency move. Higher rates compress pharma sector valuation multiples as investors rotate toward bonds, but Alembic's 10.2x P/S suggests growth expectations already embedded. Capex financing ($0.5B annually) is internally funded from $0.9B operating cash flow, eliminating borrowing cost sensitivity.
minimal - Receivables concentrated among large US wholesalers (McKesson, Cardinal Health, AmerisourceBergen) with 30-60 day terms and <1% bad debt historically. India hospital/distributor credit risk higher but mitigated by advance payments. No meaningful exposure to consumer credit or financing operations.
growth - 40.9% revenue growth and 15.7% EPS growth attract momentum investors despite recent 10.1% six-month decline. High 10.2x P/S valuation (vs 2-4x for mature generics peers) prices in continued ANDA approval pipeline and India market share gains. Low 1.4% FCF yield and zero dividend (implied by 0.00 D/E and reinvestment focus) deters income investors. Volatility from binary regulatory events (USFDA approvals/warning letters) and quarterly US pricing surprises suits risk-tolerant growth mandates.
high - Pharmaceutical stocks exhibit 25-35% annual volatility driven by regulatory binary events, quarterly earnings surprises from US pricing, and sector rotation. Alembic's -6.2% three-month and -10.1% six-month returns amid 40.9% revenue growth illustrate disconnect between fundamentals and sentiment. Small-cap liquidity ($24.6B market cap) and 70% institutional ownership amplify intraday swings on news flow.